CPT code 87494 represents a laboratory multiplex test that simultaneously detects Chlamydia trachomatis and Neisseria gonorrhoeae using an amplified nucleic acid probe technique. This type of combined molecular diagnostic is important nationally for sexually transmitted infection (STI) screening, case detection, and public health surveillance because it increases efficiency by testing for two common bacterial STIs in a single assay and supports timely treatment and contact tracing.

Key payers addressed in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for combined chlamydia/gonorrhea molecular testing, typical sites of service where the assay is performed, and how CPT code 87494 is positioned within laboratory service lines. The publication outlines benchmarking and coverage considerations, common billing practices, and relevant policy updates that affect reimbursement and coding workflows. When payer-specific coverage policies or reimbursement benchmarks are not available in the input, the report notes that data are not available.

This summary equips laboratory administrators, billing professionals, and policy analysts with the essential clinical and coding description of CPT code 87494, the primary applications of the assay, and the topics covered in the full publication, including payer coverage patterns, billing nuances, and operational implications for laboratories and clinicians involved in STI testing.